Targeting CK5+ Basal Cells to Prevent Prostate Cancer Recurrence

The patent applies preliminary action by targeting basal epithelial cells before they can progress to androgen-independent tumor cells. By administering agents that inhibit basal cell proliferation (such as ERβ agonists, DNA methyltransferase inhibitors, or PI3K/Akt pathway inhibitors) in combination with ADT, the treatment prevents the development of resistance rather than addressing it after it occurs. This proactive approach to eliminating the cell population that gives rise to resistant tumors extends treatment effectiveness beyond the typical duration limits of ADT alone.

The patent applies universality by using combination therapies that simultaneously target multiple cell types and pathways. For example, ERβ agonists like lasofoxifene not only inhibit luminal cell growth through estrogen receptor signaling but also directly suppress basal cell proliferation. Similarly, DNA methyltransferase inhibitors restore expression of tumor suppressor genes in both luminal and basal cells, while PI3K/Akt pathway inhibitors block survival signals in both cell populations. This multi-functional approach ensures comprehensive coverage of all prostate epithelial cell types involved in cancer progression.

The patent applies merging by combining agents with different mechanisms of action into unified treatment regimens. For instance, the combination of an ERβ agonist (targeting both luminal and basal cells through hormone signaling) with a DNA methyltransferase inhibitor (restoring tumor suppressor gene expression) creates a synergistic effect where the two agents work together to target basal epithelial cells through complementary pathways. This merging of multiple therapeutic approaches into a single combination regimen achieves superior recurrence prevention while managing complexity through coordinated action rather than sequential or separate treatments.